

1 **Pandemic ST131 *Escherichia coli* presenting the UPEC/EAEC and ExPEC/EAEC**
2 **hybrid pathotypes recovered from extraintestinal infections in a clinical setting of the**
3 **Brazilian Amazon region**

4

5 Nathália M. S. Bigli¹, Érica L. Fonseca^{1,*}, Fernanda S. Freitas¹, Sérgio M. Morgado¹ and
6 Ana Carolina P. Vicente¹

7

8 ¹Laboratório de Genética Molecular de Microrganismos, Instituto Oswaldo Cruz, FIOCRUZ,
9 Rio de Janeiro, Brazil.

10

11 Correspondence: Érica L. Fonseca, ericafon@ioc.fiocruz.br

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 *Escherichia coli* is part of the commensal microbiota of human's and animal's gut.
28 However, they may become pathogenic due to the acquisition of virulence factors that
29 provide the ability to cause intestinal or extraintestinal infections, which makes *E. coli* the
30 main cause of diarrheagenic diseases and urinary tract infections (UTIs) worldwide,
31 respectively. Some strains, known as hybrids, may harbour a mix of virulence determinants
32 of both diarrheagenic (DEC) and extraintestinal *E. coli* (ExPEC) pathotypes. Reports of
33 hybrid *E. coli* in Brazil are rare, and the lineages associated with such pathotypes were poorly
34 explored. This study aimed to characterize *E. coli* strains recovered from extraintestinal
35 infections in a clinical setting of the Brazilian Amazon Region by means of lineage
36 determination, antibiotic resistance profile, and investigation of DEC and ExPEC virulence
37 markers. Fifteen ExPEC strains were recovered from distinct extraintestinal sites from
38 inpatients of the General Hospital of Roraima (GHR), placed in the Brazilian Amazon region.
39 Antibiotic susceptibility test revealed that all strains were multidrug-resistant and most of
40 them, including those recovered from urine, were resistant to fluoroquinolones, the main
41 therapeutic option for treating UTIs, probably due to the presence of Ser83Leu and
42 Asp87Asn substitutions in GyrA. The MLST analysis revealed the polyclonal nature of these
43 ExPEC strains since 11 STs were determined, including local and pandemic lineages, such as
44 ST69 and ST131. Among the 15 isolates, 12 were classified as hybrids, due to the presence of
45 the *aggR* virulence marker of the Enteroaggregative *E. coli* (EAEC) pathotype together with
46 at least one ExPEC (*iutA*, *KPSMTII*, *sfaDE*, *papC*, *afaBC*, *iucD*) or Uropathogenic *E. coli*
47 (UPEC) (*vat*, *fuyA*, *chuA* and *yfcV*) virulence determinants. These UPEC/EAEC (n=10) and
48 ExPEC/EAEC (n=2) hybrid strains were found among distinct lineages, including new STs,
49 and phylogroups (ST131/B2; ST1196/AxB1; ST9403/A; ST12394/A; NEW1-CC14/B2;
50 NEW2-CC155/B1; NEW3-CC155/B1; NEW4-CC131/B2) and, for the first time, a hybrid

51 phenotype was found in the pandemic ST131 lineage in Brazil. Therefore, this study provides
52 new information on the epidemiological scenario of hybrid *E. coli* strains, contributing to a
53 better understanding of the occurrence and pathogenic potential of these organisms.

54

55 Keywords: HyPEC; ExPEC; ST69; ST131; virulence marker; pandemic lineage

56

57 INTRODUCTION

58 *Escherichia coli* inhabits the intestinal tract of humans and other animals as an
59 important member of their microbiota [1]. However, the acquisition by horizontal gene
60 transfer of virulence determinants by certain *E. coli* clones has enabled them to cause not
61 only intestinal but also extraintestinal infections in different hosts. In this way, based on the
62 body site of infection, the host, and the presence of specific virulence markers, these bacteria
63 can be classified into diarrheagenic (DEC), mainly featured by the presence of specific
64 virulence factors directly related to diarrhoea, and extraintestinal pathogenic (ExPEC) *E. coli*,
65 defined primarily by their site of isolation [2]. The DEC group encompasses several
66 pathotypes, including enterotoxigenic (ETEC), enteropathogenic (EPEC), enteroinvasive
67 (EIEC), enteroaggregative (EAEC), and Shiga toxin-producing (STEC) *E. coli*. EPEC and
68 EAEC are considered the major pathotypes of diarrheagenic *E. coli* causing disease
69 worldwide, including in Brazil. These pathotypes carry genetic determinants involved with
70 disease development and can be used as molecular markers of the pathotype.

71 The ExPEC group includes the pathotypes neonatal meningitis-associated (NMEC),
72 human sepsis-associated (SEPEC), avian pathogenic (APEC), and uropathogenic (UPEC) *E.*
73 *coli*, which is the most prevalent pathotype among extraintestinal infections worldwide.

74 UPEC is particularly associated with urinary tract infections (UTIs) and is a leading cause of

75 both community-acquired and healthcare-associated UTIs. Currently, the most frequently
76 reported high-risk ExPEC lineages belonging to the MLST sequence type ST131, ST69,
77 ST10, ST405, ST38, ST95, ST648, ST73 and ST1193, which are known for their high
78 prevalence in extraintestinal infections worldwide and for their significant role in global
79 spread of multidrug resistance [3].

80 Studies *in vivo* revealed that the presence of at least two of five virulence genes (*pap*,
81 *afa/dra*, *sfa*, *kpsMTII*, and *iut/iuc*) could be enough to cause extraintestinal infection in
82 immunocompetent individuals [4], and that *E. coli* co-harboring of *chuA*, *fyuA*, *vat*, and *yfcV*
83 virulence genes were able to cause UTIs [5]. Additionally, due to horizontal gene transfer
84 events, organisms may emerge as hybrid strains capable of causing intestinal and
85 extraintestinal diseases due to the presence of virulence factors of both ExPEC and DEC
86 pathotypes [6].

87 Strains harbouring a blend of virulence markers of different pathotypes have been
88 described worldwide in both high-risk and local lineages, however, most of them correspond
89 to hetero-pathogenic strains (characterized by a combination of virulence markers from DEC
90 pathotypes) [7-9]. A recent study in South Africa demonstrated the high prevalence of several
91 different DEC hybrid pathotypes, including strains sharing three virulence markers of three
92 different DEC pathotypes, which were recovered from inanimate surfaces and presented a
93 higher resistance profile compared to the classic pathotypes identified [8]. Another report
94 demonstrated the occurrence of different DEC hybrid strains recovered from healthy
95 individuals in Mexico [9].

96 In Brazil, few studies have characterized and reported the occurrence of hybrid
97 strains in extraintestinal infection cases harbouring the combination of DEC and ExPEC or
98 UPEC virulence markers, such as UPEC/EAEC, UPEC/aEPEC, ExPEC/STEC,

99 ExPEC/aEPEC [10-18]. However, there is a lack of association concerning the STs of such
100 hybrid strains circulating in the country. Moreover, most of these reports on hybrid strains
101 were restricted to São Paulo, a cosmopolitan city of the Southeast Brazilian region, and until
102 now, all studies reporting *E. coli* infections in the Amazon Region were associated only with
103 diarrheagenic infections [19-22]. Therefore, further studies are required to investigate the
104 distribution and potential impact of these strains on the clinical outcomes of affected
105 individuals. For these reasons, the objective of this study was to characterize *E. coli* strains
106 recovered from extraintestinal infections in the Brazilian Amazon Region by means of
107 lineage determination (MLST), antibiotic resistance profile, and investigation of DEC and
108 ExPEC virulence markers.

109 **METHODS**

110 **Clinical data, bacterial strains and antimicrobial susceptibility test**

111 From December 2016 to February, 2018, 15 *E. coli* isolates were recovered from
112 extraintestinal infection cases at the General Hospital of Roraima (GHR), placed in Boa
113 Vista. The strains were isolated from blood (n=2), urine (n=7), catheter tip (n=1), vagina
114 secretion (n=1), leg secretion (n=1), soft tissue (n=1), and operative wound secretion (n=2).
115 Species identification was performed with the automated VITEK2, and confirmed by
116 sequencing the 16S rRNA and the MLST genes. These strains are part of the Bacterial
117 Culture Collection of the Laboratory of Molecular Genetics of Microorganisms, FIOCRUZ.

118 **Antimicrobial Susceptibility testing**

119 The antibiotic susceptibility profile was determined by disc-diffusion method
120 according to clinical and laboratory standards institute (CLSI) guidelines [23] For the
121 following antibiotics: gentamicin, amikacin, kanamycin, tobramycin, neomycin,
122 streptomycin, imipenem, meropenem, ertapenem, cephalothin, cefoxitin, cefuroxime,
123 ceftazidime, ceftriaxone, cefotaxime, cefepime, azithromycin, clarithromycin, erythromycin,
124 ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanic acid, carbenicillin,
125 penicillin, aztreonam, piperacillin/tazobactam, ticarcillin/clavulanic acid, nalidixic acid,
126 ciprofloxacin, norfloxacin, levofloxacin, ofloxacin, colistin sulphate, sulphonamide,
127 trimethoprim, sulfamethoxazole/trimethoprim, chloramphenicol, fosfomycin, nitrofurantoin,
128 tetracycline and minocycline.

129 **Genotyping by Multilocus sequence typing (MLST)**

130 The genetic relationship among the ExPEC strains was established by MLST based
131 on the Achtman MLST scheme (*adh*, *fumC*, *gyrB*, *icd*, *mdh*, *purA* and *recA*)
132 (<http://mlst.warwick.ac.uk>). Clonal complexes (CCs) were considered when sequence types
133 (STs) shared five or more identical alleles taking into account the seven genes considered in
134 the MLST scheme.

135 **Detection of resistance genes by polymerase chain reaction (PCR) and sequencing**

136 The isolates were screened by PCR and sequencing for the presence of the genes
137 frequently associated with β -lactam resistance in *E. coli* such as
138 *bla*_{SHV}, *bla*_{GES}, *bla*_{TEM}, *bla*_{CTX-M} (class A β -lactamases). The plasmid-mediated
139 fluoroquinolone (FQ) resistance *qnr* genes and the presence of mutations in the quinolone
140 resistance-determining region (QRDR) of *gyrA* was also investigated (Table 1).

141 **Molecular Characterization of Hybrid Strains**

142 The presence of DEC and ExPEC virulence determinants was screened by PCR
143 (Table 1). Those strains presenting at least one of the DEC pathotypes virulence markers
144 were considered hybrid strains [13]. The DEC virulence factors screened were *eae* and *bfpB*
145 genes, associated with epithelial adhesion in EPEC; the *aggR* gene, a universal regulator of
146 EAEC virulence involved with the aggregative adhesion fimbriae (AAF) production; the *stx1*
147 and *stx2* genes, related to the Shiga toxins production in STEC; the *estH*, *estP* and *eIT*,
148 involved with the production of heat-stable and heat-labile toxins in ETEC; the *invE* gene that
149 encodes a regulatory protein that controls the transcriptional of invasion genes in EIEC
150 pathotype; the *vat*, *fuyA*, *chuA* and *yfcV*, all markers of UPEC; and ExPEC markers *iutA*,
151 *KPSMTII*, *sfaDE*, *papC*, *afaBC*, *iucD*.

152

153 **RESULTS AND DISCUSSION**

154 The phenotypic analysis revealed that all *E. coli* ExPEC strains (n=15) were classified as
155 multidrug-resistant (MDR) according to resistance classification criteria [24] (Table 1).
156 Among the β -lactam antibiotics, all isolates were resistant to at least one of these antibiotics,
157 and such phenotype could be explained by the presence of the *bla*_{TEM} gene in 14/15 isolates.
158 In fact, *bla*_{TEM} is frequently associated with plasmids in *E. coli*, and it was the most prevalent
159 gene among ExPEC recovered from UTI cases in São Paulo, Brazil [25]. However, although
160 the *bla*_{CTX-M} has been frequently associated with ExPEC in Brazil and worldwide [26], this
161 gene was not found in our sample, as well as the other screened β -lactamase genes *bla*_{GES} and
162 *bla*_{SHV}.

163 Moreover, a high prevalence of fluoroquinolone resistance was observed (73%)
164 among the ExPEC strains. Although none of them carried any *qnr* allele, all FQ-resistant
165 isolates presented mutations in the Quinolone Resistance-Determining Region (QRDR) of
166 *gyrA* that led to the amino acid substitution Ser83Leu and Asp87Asn, known to be involved

167 with FQ resistance emergence [27]. Interestingly, these substitutions were recently reported
168 as the determinants of FQ resistance in ExPEC strains recovered from UTI cases in São Paulo
169 [12].

170 The MLST analysis revealed a great diversity, in which 11 STs were assigned to the
171 15 ExPEC strains: ST69, ST131, ST8886, ST1196, ST9403, ST3180, ST12394, and four
172 different new sequence types belonging to CC155 (n=2), CC14 (n=1) and CC131 (n=1),
173 demonstrating the polyclonal nature of these hybrid strains. The most prevalent lineage
174 among our sample was ST131, a pandemic clonal complex of the B2 phylogroup often
175 associated with an arsenal of resistance and virulence genes, contributing to the success of
176 this clone in spreading through clinical settings worldwide. The ST69 is another pandemic
177 lineage belonging to the phylogroup D usually associated with clinics and food/environment
178 contamination in several countries [27]. As found here, Lara and Colleagues have
179 demonstrated the occurrence of ExPEC ST69 presenting the hybrid pathotype UPEC/EAEC
180 in Brazil [10]. However, in spite of ST131 prevalence in Brazil, this is the first report of this
181 lineage presenting a hybrid pathotype (UPEC/EAEC) in that country (Table 2).

182 Considering the *E. coli* virulome, 9/19 virulence factors characterizing DEC and
183 ExPEC pathotypes were found in the studied samples in different frequencies and
184 combinations (Table 2). The presence of at least one extraintestinal virulence marker was
185 observed in all isolates, corroborating the nature of the infection sites from which they were
186 recovered. The *iucD* gene, which is part of the operon involved with aerobactin siderophore
187 synthesis, was the most prevalent ExPEC marker among the isolates (12/15). This gene is
188 associated with iron uptake systems, facilitating its survival and pathogenicity and playing a
189 crucial role in the bacteria's ability to cause infections and evade the host's immune response.
190 Among the 15 ExPEC isolates analysed, 12 (80%) had at least one marker used to define
191 ExPEC and DEC pathotypes, being characterized as hybrid strains. The three strains

192 classified as non-hybrids belonged to the pandemic lineages ST131/phylogroup B2 (EC44)
193 and ST69/phylogroup D (EC39) and to the local ST8886 (EC40). Only 13 entries in
194 Enterobase (<https://enterobase.warwick.ac.uk/species/index/ecoli>) have been found for
195 ST8886, and in most cases, they corresponded to strains recovered from environmental sites
196 in USA in 2015 and only one recovered from an animal source in Canada in 2022. Thus, this
197 study reported the first clinical case belonging to this lineage.

198 Concerning the hybrid strains, it was verified the presence of UPEC/EAEC (n=10)
199 and ExPEC/EAEC (n=2) (when UPEC markers were absent, or the strain had been recovered
200 from a different body site other than urine). The *aggR* gene, considered a diarrheagenic factor
201 that defines the EAEC pathotype, was found in all hybrid isolates, indicating that they would
202 have the ability to cause intestinal disorders despite presenting in extraintestinal infections.
203 EAEC is recognized as an important cause of diarrhoea worldwide and can be considered the
204 most common DEC pathotype in *E. coli* in Brazil. However, *E. coli* strains with a hybrid
205 enteroaggregative/uropathogenic (UPEC/EAEC) genotype have sporadically emerged as a
206 cause of extraintestinal infections in Brazil [10-18]. Here we demonstrated the high
207 prevalence of such hybrid pathotypes in distinct lineages causing infections in the Amazon
208 region.

209 Most of UPEC/EAEC hybrid strains belonged to the pandemic and widespread ST131
210 (one of them was assigned to a new ST of the CC131) (Table 2). They were recovered from
211 distinct extraintestinal sites and presented a heterogeneous profile of virulence markers. The
212 unique non-hybrid ST131 strain was the EC44, which was a UPEC recovered from UTI that
213 presented both UPEC and ExPEC virulence markers. On the other hand, local STs (ST9403,
214 ST3180 and ST12394) belonging to different phylogroups (A, B1 and B2) and recovered
215 from distinct body sites, including blood, were also classified as UPEC/EAEC hybrid strains.

216 Interestingly, in spite of the diversity of infection sites, most of the ExPEC strains were
217 recovered from urine, and all but one were resistant to the tested fluoroquinolones (Table 2),
218 which are the first choice antibiotics for treating UTIs. These findings probably accounted for
219 treatment failure, compromising the success of clinical outcomes.

220 Interestingly, in spite of the UPEC/EAEC EC49 strain being a new local ST of
221 CC14/phylogroup B2, this isolate exhibited the highest number of ExPEC and UPEC
222 virulence markers, besides the EAEC marker *aggR* (Table 2). This demonstrates that not only
223 pandemic high-risk clones display an enhanced pathogenicity and that emerging strains may
224 possess a high level of virulence fitness.

225 The other class of hybrids (ExPEC/EAEC) corresponded to strains (n=2) that
226 carried ExPEC virulence markers and the *aggR* EAEC marker. The strains belonged to a new
227 ST from CC155/phylogroup B1 (EC52) and to the local ST1196 belonging to phylogroup
228 AxB1 (EC47) (Table 2). A recent study in Mozambique demonstrated that a hybrid
229 ExPEC/EAEC strain recovered from blood belonged to the pandemic ST131 lineage and
230 presented a remarkable virulence profile [28]. These findings revealed that ExPEC/EAEC
231 hybrids are associated with distinct lineages. Interestingly, both ExPEC/EAEC strains
232 identified here were recovered from urine although no UPEC virulence marker had been
233 identified. This was also the case of the non-hybrid EC39 strain, belonging to the pandemic
234 ST69/phylogroup D, that had been characterized as a UPEC pathotype due to the site of
235 infection (urine), although all UPEC virulence markers were absent (Table 2). These
236 findings suggest that their ability to infect the urinary tract would be related to other
237 mechanisms that were not investigated in this study. In fact, UPEC employs various virulence
238 strategies, such as binding to urinary tract epithelial cells, iron acquisition, toxin production,
239 and evasion of the host's immune system. These virulence factors are commonly encoded by

240 genes found in pathogenicity islands (PAIs), which are often mobilized through horizontal
241 gene transfer and could have been lost from those UPEC strains [14]. Furthermore, the
242 presence of UPEC factors in strains recovered from sites other than urine, such as the non-
243 hybrid EC40 strain (Table 2), demonstrates their ability to colonize and survive in the urinary
244 tract, but also that other virulence determinants were involved in the establishment of
245 extraintestinal infections in those cases.

246 **CONCLUSION**

247 This study contributes to a better understanding of the occurrence and pathogenic
248 potential of hybrid strains of *E. coli*. Besides, the association of pathotype and lineage
249 definition provides new information in the scenario of the global epidemiology of ExPEC
250 hybrid strains.

251

252 **Funding information**

253 This work was supported by Oswaldo Cruz Institute grant, Fundação Coordenação de
254 Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de
255 Desenvolvimento Científico e Tecnológico (CNPq) and Fundação Carlos Chagas Filho de
256 Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Processo SEI-
257 260003/019688/2022.

258

259 **Conflicts of interest**

260 The authors declare that there are no conflicts of interest.

261

262 **Ethical statement**

263 This study was approved by the Oswaldo Cruz Foundation Ethics Committee (CAAE:
264 39978114.5.0000.5248).

265

266 **References**

- 267 1. **Leimbach A, Hacker J, Dobrindt U.** E. coli as an all-rounder: the thin line between
268 commensalism and pathogenicity. *Curr Top Microbiol Immunol* 2013;358:3-32.
- 269 2. **Sora VM, Meroni G, Martino PA, Soggiu A, Bonizzi L, et al.** Extraintestinal
270 Pathogenic Escherichia coli: Virulence Factors and Antibiotic Resistance. *Pathogens*
271 2021;10:1355.
- 272 3. **Kocsis B, Gulyás D, Szabó D.** Emergence and Dissemination of Extraintestinal
273 Pathogenic High-Risk International Clones of Escherichia coli. *Life (Basel)* 2022;
274 12:2077.
- 275 4. **Johnson JR, Murray AC, Gajewski A, Sullivan M, Snippes P, et al.** Isolation and
276 molecular characterization of nalidixic acid-resistant extraintestinal pathogenic
277 Escherichia coli from retail chicken products. *Antimicrob Agents Chemother*
278 2003;47:2161-2168.
- 279 5. **Spurbeck RR, Dinh PC Jr, Walk ST, Stapleton AE, Hooton TM, et al.**
280 Escherichia coli isolates that carry vat, fyuA, chuA, and yfcV efficiently colonize the
281 urinary tract. *Infect Immun* 2012;80:4115-4122.
- 282 6. **Braz S, Melchior K, Moreira CG.** Escherichia coli as a Multifaceted Pathogenic and
283 Versatile Bacterium. *Front Cell Infect Microbiol* 2020;10:1–9.
- 284 7. **Lee W, Sung S, Ha J, Kim E, An ES, et al.** Molecular and Genomic Analysis of the
285 Virulence Factors and Potential Transmission of Hybrid Enteropathogenic and
286 Enterotoxigenic Escherichia coli (EPEC/ETEC) Strains Isolated in South Korea. *Int J*
287 *Mol Sci* 2023;24:12729.

- 288 8. **Rakhaluru P, Munzhedzi L, Abia ALK, Kabue JP, Potgieter N, et al.** Prevalence
289 and Antimicrobial Resistance Profile of Diarrheogenic *Escherichia coli* from Fomites
290 in Rural Households in South Africa. *Antibiotics (Basel)* 2023;12:1345.
- 291 9. **Méndez-Moreno E, Caporal-Hernandez L, Mendez-Pfeiffer PA, Enciso-**
292 **Martínez Y, López RR, et al.** Characterization of Diarrheogenic *Escherichia coli*
293 Strains Isolated from Healthy Donors, including a Triple Hybrid Strain. *Antibiotics*
294 (*Basel*) 2022;11:833.
- 295 10. **Lara FBM, Nery DR, Oliveira PM, Araujo ML, Carvalho FRQ, et al.** Virulence
296 Markers and Phylogenetic Analysis of *Escherichia coli* Strains with Hybrid
297 EAEC/UPEC Genotypes Recovered from Sporadic Cases of Extraintestinal
298 Infections. *Front Microbiol* 2017;8:146.
- 299 11. **Schüroff PA, Abe CM, Silva JW, Coelho CP, Andrade FB, et al.** Role of
300 aggregate-forming pilus (AFP) in adherence and colonization of both intestinal and
301 urinary tracts. *Virulence* 2022;13:1423-1433.
- 302 12. **Nascimento JAS, Santos FF, Valiatti TB, Santos-Neto JF, Santos ACM, et al.**
303 Frequency and Diversity of Hybrid *Escherichia coli* Strains Isolated from Urinary
304 Tract Infections. *Microorganisms* 2021;9:693.
- 305 13. **Nascimento JAS, Santos FF, Santos-Neto JF, Trovão LO, Valiatti TB, et al.**
306 Molecular Epidemiology and Presence of Hybrid Pathogenic *Escherichia coli* among
307 Isolates from Community-Acquired Urinary Tract Infection. *Microorganisms* 2022;
308 10:302.

- 309 14. **Tanabe RHS, Dias RCB, Orsi H, de Lira DRP, Vieira MA, et al.** Characterization
310 of Uropathogenic Escherichia coli Reveals Hybrid Isolates of Uropathogenic and
311 Diarrheagenic (UPEC/DEC) E. coli. *Microorganisms* 2022;10:645.
- 312 15. **Furlan JPR, Ramos MS, Dos Santos LDR, Rosa RS, Stehling EG.** Multidrug-
313 resistant Shiga toxin-producing Escherichia coli and hybrid pathogenic strains of
314 bovine origin. *Vet Res Commun* 2023; online ahead of print.
- 315 16. **Munhoz DD, Richards AC, Santos FF, Mulvey MA, Piazza RMF.** E. coli
316 Common pili promote the fitness and virulence of a hybrid aEPEC/ExPEC strain
317 within diverse host environments. *Gut Microbes* 2023;15:2190308.
- 318 17. **de Lira DRP, Cavalcanti AMF, Pinheiro SRS, Orsi H, Dos Santos LF, et al.**
319 Identification of a hybrid atypical enteropathogenic and enteroaggregative Escherichia
320 coli (aEPEC/EAEC) clone of serotype O3:H2 associated with a diarrheal outbreak in
321 Brazil. *Braz J Microbiol* 2021;52:2075-2079.
- 322 18. **Valiatti TB, Santos FF, Santos ACM, Nascimento JAS, Silva RM, et al.** Genetic
323 and Virulence Characteristics of a Hybrid Atypical Enteropathogenic and
324 Uropathogenic Escherichia coli (aEPEC/UPEC) Strain. *Front Cell Infect Microbiol*
325 2020;10:492.
- 326 19. **Vicente AC, Teixeira LF, Iniguez-Rojas L, Luna MG, Silva L, et al.** Outbreaks of
327 cholera-like diarrhoea caused by enterotoxigenic Escherichia coli in the Brazilian
328 Amazon Rainforest. *Trans R Soc Trop Med Hyg* 2005;99:669-674.
- 329 20. **Benevides-Matos N, Pieri FA, Penatti M, Orlandi PP.** Adherence and virulence
330 genes of Escherichia coli from children diarrhoea in the Brazilian Amazon. *Braz J*
331 *Microbiol* 2015;46:131-137.

- 332 21. **Taborda RLM, Silva LAD, Orlandi PP, Batista FS, Rodrigues RS, et al.**
333 Characterization of enteroaggregative Escherichia coli among diarrheal children in
334 Western Brazilian Amazon. *Arq Gastroenterol* 2018;55:390-396.
- 335 22. **Rodrigues RS, Lima NCDS, Taborda RLM, Esquerdo RP, Gama AR, et al.**
336 Antibiotic resistance and biofilm formation in children with Enteropathogenic
337 Escherichia coli (EPEC) in Brazilian Amazon. *J Infect Dev Ctries* 2019;13:698-705.
- 338 23. **Clinical and Laboratory Standards Institute.** *Performance Standards for*
339 *Antimicrobial Susceptibility Testing supplement M100.* 32nd Ed. Wayne, PA: CLSI;
340 2021.
- 341 24. **Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al.**
342 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria an
343 international expert proposal for interim standard definitions for acquired resistance.
344 *Clin Microbiol Infect* 2012;18:268–281.
- 345 25. **Santos-Neto JF, Santos ACM, Nascimento JAS, Trovão LO, Santos FF, et al.**
346 Virulence Profile, Antibiotic Resistance, and Phylogenetic Relationships among
347 Escherichia coli Strains Isolated from the Feces and Urine of Hospitalized Patients.
348 *Pathogens* 2022;11:1528.
- 349 26. **Bevan ER, Jones AM, Hawkey PM.** Global epidemiology of CTX-M β -lactamases:
350 temporal and geographical shifts in genotype. *J Antimicrob Chemother* 2017;
351 72:2145–2155.
- 352 27. **Riley LW.** Pandemic lineages of extraintestinal pathogenic Escherichia coli. *Clin*
353 *Microbiol Infect* 2014;20:380-390.
- 354 28. **Santona A, Sumbana JJ, Fiamma M, Deligios M, Taviani E, et al.** High-risk
355 lineages among extended-spectrum β -lactamase-producing Escherichia coli from

356 extraintestinal infections in Maputo Central Hospital, Mozambique. *Int J Antimicrob*

357 *Agents* 2022;60:106649.

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382 **Table 1. Primers used in this study**

Primer name	Primer sequence (5' – 3')	Target
Antibiotic resistance genes		
SHV F	TTCATGGCGTTACCTTTGAC	Class A β -lactamase <i>bla</i> _{SHV} genes
SHV R	CCGACAGAGTGC GG TATTTA	
GES F	ATGCGCTTCATTACGCAC	ESBL Class A β -lactamase <i>bla</i> _{GES} genes
GES R	CTATTTGTCCGTGCTCAGGA	
TEM F	GTATCCGCTCATGAGACAATA	Class A β -lactamase <i>bla</i> _{TEM} genes
TEM R	TCTAAAGTATATATGAGTAAACTTGGTCTG	
CTX-M F	CGCTTTGCGATGTGCAG	ESBL Class A β -lactamase <i>bla</i> _{CTX-M} genes
CTX-M R	ACCGCGATATCGTTGGT	
QnrVC F	AAGTGAACCTTCTCACATCAGG	Quinolone resistance <i>qnrVC</i> genes
QnrVC R	ATGATTACCCCTAATTGCTCC	
QnrA F	GATTTCTCACGCCAGGATTT	Quinolone resistance <i>qnrA</i> gene
QnrA R	TCKGAGCCCATCAAGGAAG	
QnrB F	GATCGWGAAAGYCAGAAAGG	Quinolone resistance <i>qnrB</i> gene
QnrB R	CCACARYTCRCAYTTTTTC	
QnrC F	TGCAGACCTACGAGATGCTT	Quinolone resistance <i>qnrC</i> gene
QnrC R	TTCACGCCAGTTAAATCCAC	
QnrS F	ACGTGTTAACTTGC GTGAT	Quinolone resistance <i>qnrS</i> gene
QnrS R	GCAATTTTGATACCTGATG	
GyrA F	CGTTGGTGACGTAATCGGTA	QRDR of <i>gyrA</i> gene
GyrA R	GTGTTCCATCAGCCCTTCA	
Virulence genes		
Eae F	GTGGCGAATACTGGCGAGACT	EPEC virulence marker
Eae R	CGACGGTGAAAAAGAATGGGG	
BfpB F	CGATAAACTGATACTGGGCAGC	EAEC virulence marker
BfpB R	GTGCTTCCCGAACAGTCACT	
AggR F	CGATACATTAAGACGCCTAAAG	STEC virulence marker
AggR R	TCTGATACATTA AATTCATCTGC	
Stx1 F	CAGTTAATGTGGTGGCGAAGG	STEC virulence marker
Stx1 R	CACCAGACAATGTAACCGCTG	
Stx2 F	ATCCTATTCCCGGGAGTTTACG	STEC virulence marker
Stx2 R	GCGTCATCGTATACACAGGAGC	
EstH F	GCTAAACCAGTAGAGTC	ETEC virulence marker
EstH R	CACCCGGTACAAGCAGG	
EstP F	AGTCAGTCAACTGAATCAC	ETEC virulence marker
EstP R	ATTTTCTCAGCACC AATAC	
eIT F	CACACGGAGCTCCTCAG	EIEC virulence marker
eIT R	CAAAC TAGTTTTCCATACTG	
invE F	CGATAGATGGCGAGAAATTATATCCCG	EIEC virulence marker
invE R	CGATCAAGAATCCCTAACAGAAGAATCA	
Vat F	TCAGGACACGTT CAGGCATT CAGT	UPEC virulence marker
Vat R	GGCCAGAACATTTGCTCCCTTGTT	
FyuA F	GTAACAATCTTCCCGCTCGGCAT	UPEC virulence marker
FyuA R	TGACGATTAACGAACCGGAAGGGA	
ChuA F	CTGAAACCATGACCGTTACG	UPEC virulence marker
ChuA R	TTGTAGTAACGCACTAAACC	
yfcV F	ACATGGAGACCAGTTCACC	

yfcV R	GTAATCTGGAATGTGGTCAGG	
iutA F	GGCTGGACATCATGGGAACTGG	
iutA R	CGTCGGGAACGGGTAGAATCG	
KpsMTII F	GCGCATTTGCTGATACTGTTG	
KpsMTII R	CATCCAGACGATAAGCATGAGCA	
sfaDE F	CTCCGGAGAACTGGGTGCATCTTAC	
sfaDE R	CGGAGGAGTAATTACAAACCTGGCA	
papC F	GTGGCAGTATGAGTAATGACCGTTA	ExPEC virulence marker
papC R	ATATCCTTTCTGCAGGGATGCAATA	
afaBC F	GGCAGAGGGCCGGCAACAGGC	
afaBC R	CCCGTAACGCGCCAGCATCTC	
iucD F	TCCTCATTTTTCTGGCATC	
iucD R	AGTTTATTTCCGCCGCTTCT	

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

Table 2. Clinical and genetic information of the hybrid *E. coli* strains in this study

Strain	Infection site	ST	CC	Phylogroup	Antibiotic resistance profile	Pathotype Genetic Markers			Hybrid Classification
						DEC	EXPEC	UPEC	
EC39	Urine	69	69	D	NEO, CEF, CLA, ERI, CB, AMP, PEN, SXT, SUL, TMP	-	<i>kpsMTH</i>	-	-
EC40	Blood	8886	-	B2	NEO, CXM, AZI, CLA, ERI, AMP, PEN, SXT, SUL, TMP KAN, NEO, STR, CEF, FOX, CXM, CAZ, CRO,	-	-	<i>fyuA, yfcV</i>	-
EC41	Leg secretion	131	131	B2	CTX, FEP, AMP, AMX, CB, PEN, TIM, CLA, ERI, NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, MIN GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM,	<i>aggR</i>	<i>iucD</i>	<i>fyuA, yfcV</i>	UPEC/EAEC
EC42	Urine	131	131	B2	CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB, PEN, TIM, ATM, CLA, ERI, NAL, CIP, NOR,	<i>aggR</i>	<i>iucD</i>	<i>yfcV</i>	UPEC/EAEC

					LEV, OFX, SXT, SUL, TMP, MIN, TET					
EC43	Catheter tip	131	131	B2	NEO, STR, CEF, FOX, CXM, CAZ, CRO, CTX, FEP, AMP, AMX, CB, PEN, TIM, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, TET	<i>aggR</i>	<i>iutA, kpsMTII, iucD</i>	<i>yfcV</i>	UPEC/EAEC	
EC46	Soft tissue	NEW 4	131	B2	GEN, TOB, KAN, NEO, CEF, FOX, CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB, PEN, TIM, ATM, CLA, NAL, CIP, NOR, LEV, OFX	<i>aggR</i>	<i>iutA, kpsMTII,</i> <i>papC, iucD</i>	<i>fyuA, yfcV</i>	UPEC/EAEC	
EC47	Urine	1196	-	AxB1	KAN, NEO, CEF, AMP, CB, PEN, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX	<i>aggR</i>	<i>iutA, afaBC</i>	-	EXPEC/EAEC	
EC48	Vagina secretion	9403	-	A	KAN, NEO, STR, AMP, CB, PEN, AZI	<i>aggR</i>	<i>iutA, kpsMTII,</i> <i>papC, iucD</i>	<i>fyuA, yfcV</i>	UPEC/EAEC	
EC44	Urine	131	131	B2	GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB, PEN, TIM, ATM, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, TET TOB, KAN, NEO, STR, CEF, FOX, CXM, CAZ,	-	<i>iutA, kpsMTII,</i> <i>papC iucD</i>	<i>fyuA, yfcV</i>	-	

EC45	Urine	131	131	B2	CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB, PEN, TIM, TZP, ATM, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP	<i>aggR</i>	<i>iutA, kpsMTII, afaBC, iucD</i>	<i>fyuA, yfcV</i>	UPEC/EAEC
EC49	Urine	NEW 1	14	B2	KAN, NEO, STR, CEF, CTX, AMP, SAM, AMX, AMC, CB, PEN, TIM, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP	<i>aggR</i>	<i>iutA, kpsMTII, papC, afaBC, iucD</i>	<i>vat, fyuA, yfcV</i>	UPEC/EAEC
EC50	-	3180	14	B2	KAN, NEO, STR, CRO, AMP, PEN, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX, CHL	<i>aggR</i>	<i>iutA, kpsMTII, iucD</i>	<i>yfcV</i>	UPEC/EAEC
EC51	Blood	NEW 2	155	B1	KAN, NEO, STR, CEF, CRO, AMP, SAM, AMX, CB, PEN, TIM, CLA, ERI, SXT, SUL, TMP, MIN, TET	<i>aggR</i>	<i>iutA, iucD</i>	<i>fyuA</i>	UPEC/EAEC
EC52	Urine	NEW 3	155	B1	AMP, PEN, CLA, NAL, CIP, NOR, LEV, OFX, MIN	<i>aggR</i>	<i>iutA, afaBC, iucD</i>	-	EXPEC/EAEC
EC53	wound secretion	12394	46	A	AMK, GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX, CB, PEN, TIM, ATM, AZI, CLA, ERI, NAL, CIP, NOR, LEV, OFX, TMP, MIN, TET	<i>aggR</i>	<i>iutA, iucD</i>	<i>fyuA</i>	UPEC/EAEC

Abbreviations: AMK, amikacin; GEN, gentamicin; TOB, tobramycin; KAN, kanamycin; NEO, neomycin; STR, streptomycin; CEF, cephalothin; FOX, ceftaxime; CXM, cefuroxime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; AMP, ampicillin; SAM, ampicillin/sulbactam; AMX, amoxicillin; AMC, amoxicillin/clavulanate; CB, carbenicillin; PEN, penicillin; TIM, ticarcillin/clavulanate; TZP, piperacillin/tazobactam; ATM, aztreonam; AZI, azithromycin; CLA, clarithromycin; ERI, erythromycin; NAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; LEV, levofloxacin; OFX, ofloxacin; SXT, trimethoprim/sulfamethoxazole; SUL, sulphamide; TMP, trimethoprim; MIN, minocycline; tetracycline; CHL, chloramphenicol.

ExPEC strains presenting hybrid pathotypes in the Amazon region

UPEC/EAEC and ExPEC/EAEC
(new STs, local STs and pandemic ST131)

